As a remission induction therapy in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), the therapeutic efficacy of mycophenolate mofetil (MMF) is similar to that of cyclophosphamide, according to a meta-analysis of data from four randomized controlled trials. In the studies, which enrolled a total of 300 patients with AAV, MMF and cyclophosphamide led to similar rates of remission at 6 months, ANCA negativity at 6 months and long-term relapse. Rates of death among patients with AAV were similar with both treatments.